{"id":"NCT00486018","sponsor":"Genentech, Inc.","briefTitle":"A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO)","officialTitle":"A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared With Sham in Subjects With Macular Edema Secondary to Branch Retinal Vein Occlusion","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-07","primaryCompletion":"2009-05","completion":"2009-11","firstPosted":"2007-06-13","resultsPosted":"2011-02-25","lastUpdate":"2017-05-10"},"enrollment":397,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Macular Edema","Retinal Vein Occlusion"],"interventions":[{"type":"DRUG","name":"Ranibizumab injection 0.3 mg","otherNames":["Lucentis"]},{"type":"DRUG","name":"Ranibizumab injection 0.5 mg","otherNames":["Lucentis"]},{"type":"DRUG","name":"Sham injection","otherNames":[]}],"arms":[{"label":"Sham injection","type":"SHAM_COMPARATOR"},{"label":"Ranibizumab injection 0.3 mg","type":"EXPERIMENTAL"},{"label":"Ranibizumab injection 0.5 mg","type":"EXPERIMENTAL"}],"summary":"This was a Phase III, multicenter, randomized, double-masked, sham injection-controlled study of the efficacy and safety of intravitreal ranibizumab compared with sham injections in patients with macular edema secondary to branch retinal vein occlusion (BRVO); 397 patients with BRVO were enrolled at 93 investigational sites in the United States. The study included a treatment period (6 months) and an observation period (6 months).","primaryOutcome":{"measure":"Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at 6 Months","timeFrame":"Baseline and 6 months","effectByArm":[{"arm":"Sham Injection","deltaMin":54.7,"sd":12.2},{"arm":"Ranibizumab Injection 0.3 mg","deltaMin":56,"sd":12.1},{"arm":"Ranibizumab Injection 0.5 mg","deltaMin":53,"sd":12.5}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":10},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["23699977","23415775"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":131},"commonTop":["Conjunctival Hemorrhage","Retinal Exudates","Eye Pain","Retinal Hemorrhage","Ocular Vascular Disorder"]}}